Tribunal Upholds Revenue's Valuation Method for Physician Samples Under Central Excise Rules

The tribunal concluded that Rule 4 of the Central Excise Valuation Rules, 2000, can be applied to physician samples, affirming the revenue's valuation method based on comparable goods. The appeal by M/s. Blue Cross Laboratories Ltd. was dismissed, upholding the demand, interest, and penalty imposed by the revenue. The tribunal found the valuation under Rule 4 appropriate, with adjustments allowed under Rule 11.

---

---

Issues Involved:
1. Valuation of physician samples cleared free of cost.
2. Applicability of Rule 4 of the Central Excise (Valuation) Rules, 2000.
3. Comparison with previous judgments and valuation methods.

Detailed Analysis:

1. Valuation of Physician Samples Cleared Free of Cost:
The appellant, M/s. Blue Cross Laboratories Ltd., challenged the confirmation of demand, interest, and imposition of penalty concerning physician samples cleared free of cost. The appellant argued that they paid duty based on cost plus a 10% margin, while the revenue demanded duty based on a pro-rata value derived from the MRP of the same medicines. The appellant cited the Larger Bench decision in their own case, which held that physician samples cannot be assessed under Rule 4 of the Central Excise (Valuation) Rules, 1975, by comparing the value with the normal trade pack.

2. Applicability of Rule 4 of the Central Excise (Valuation) Rules, 2000:
The appellant contended that Rule 4 of the Central Excise Valuation Rules cannot be applied to physician samples. They relied on the Supreme Court decision in Biochem Pharmaceuticals Industries Ltd., which discussed Rule 6(b) of the 1975 Rules, stating that valuation should be based on comparable goods or the cost of production plus profits. However, the revenue argued that Rule 4 of the 2000 Rules is applicable, as supported by the Bombay High Court decision in Indian Drugs Manufacturer’s Association, which held that physician samples should be valued under Rule 4 of the 2000 Rules.

3. Comparison with Previous Judgments and Valuation Methods:
The revenue relied on the Bombay High Court decision in Indian Drugs Manufacturer’s Association, which comprehensively addressed the valuation of physician samples. The court held that Rule 4 of the 2000 Rules applies to physician samples, as these samples are not sold but are comparable to goods sold in the market. The court emphasized that Rule 8, which deals with captively consumed goods, is not applicable to physician samples. The court also clarified that adjustments can be made under Rule 4 to account for differences in packing and marking.

The appellant also cited the Gujarat High Court decision in Tuton Pharmaceuticals, which held that valuation under Section 4A cannot be applied to physician samples. However, the tribunal noted that this decision did not consider the Bombay High Court’s ruling in Indian Drugs Manufacturer’s Association, which is directly relevant to the current case.

Conclusion:
The tribunal concluded that the Bombay High Court’s decision in Indian Drugs Manufacturer’s Association is applicable and that Rule 4 of the Central Excise Valuation Rules, 2000, can be applied to physician samples. The tribunal dismissed the appeal, affirming the revenue’s method of valuation based on comparable goods under Rule 4, with necessary adjustments as per Rule 11 of the Central Excise Valuation Rules, 2000. The tribunal found no merit in the appellant’s arguments and upheld the impugned order.

---